EU
ALXN

Emory University’s Alexion Pharmaceuticals ALXN Stock Holding History

Emory University’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-18,235
Closed -$2.39M – 45
2019
Q2 		$2.39M Sell
18,235
-194
-1% -$25K 1.68% 22
2019
Q1 		$2.49M Sell
18,429
-1,238
-6% -$154K 1.75% 15
2018
Q4 		$1.92M Sell
19,667
-3,348
-15% -$396K 1.51% 26
2018
Q3 		$3.2M Buy
23,015
+934
+4% +$117K 2.09% 7
2018
Q2 		$2.74M Buy
22,081
+288
+1% +$33.7K 1.82% 15
2018
Q1 		$2.43M Buy
21,793
+5,020
+30% +$600K 1.73% 24
2017
Q4 		$2.01M Buy
16,773
+4,490
+37% +$547K 1.72% 15
2017
Q3 		$1.72M Sell
12,283
-1,324
-10% -$180K 1.36% 29
2017
Q2 		$1.66M Sell
13,607
-3,146
-19% -$366K 1.46% 20
2017
Q1 		$2.03M Sell
16,753
-904
-5% -$117K 1.92% 17
2016
Q4 		$2.16M Buy
+17,657
New +$2.16M 2.13% 7
2015
Q3 		$1.27M Sell
8,101
-1,178
-13% -$215K 3.53% 15
2015
Q2 		$1.68M Buy
+9,279
New +$1.6M 2.27% 5

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emory University's ALXN Position: Q3 2019 in Review

Emory University sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 18,235 shares — an estimated $2.39M sold.

Emory University first reported a position in ALXN in Q2 2015 and held it in 13 quarters. The position peaked at $3.2M in Q3 2018. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Emory University reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Emory University sold 18,235 Alexion Pharmaceuticals shares in Q3 2019, an estimated $2.39M.
  • Emory University first reported a position in Alexion Pharmaceuticals in Q2 2015 and held it in 13 quarters.
  • Emory University's Alexion Pharmaceuticals position peaked at $3.2M in Q3 2018.
  • 646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Emory University's 13F filing for Q3 2019, filed 14 Nov 2019.